Carola Castiello, Panagiotis Efentakis, Panagiota-Efstathia Nikolaou, Lydia Symeonidi, Christina Chania, Ioanna Barla, Ifigeneia Akrani, Nikolaos Kostomitsopoulos, Evangelos Gikas, Nikolaos S Thomaidis, Emmanuel Mikros, Petra Kleinbongard, Rossella Fioravanti, Clemens Zwergel, Sergio Valente, Antonello Mai, Ioanna Andreadou
{"title":"通过药理激活Sirtuin 5对小鼠急性心肌梗死模型的心脏保护作用。","authors":"Carola Castiello, Panagiotis Efentakis, Panagiota-Efstathia Nikolaou, Lydia Symeonidi, Christina Chania, Ioanna Barla, Ifigeneia Akrani, Nikolaos Kostomitsopoulos, Evangelos Gikas, Nikolaos S Thomaidis, Emmanuel Mikros, Petra Kleinbongard, Rossella Fioravanti, Clemens Zwergel, Sergio Valente, Antonello Mai, Ioanna Andreadou","doi":"10.2147/DDDT.S509337","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Sirtuins (SIRTs) play a critical role in redox and metabolic regulation of the myocardium; however, the cardioprotective potential of SIRT5 in terms of infarct size (IS) reduction is still elusive. Herein, we employed the newly synthesized SIRT5-specific agonist, MC3215, developed by our group, to explore for the first time the pharmacological activation of SIRT5 as a target for cardioprotection.</p><p><strong>Methods and results: </strong>In in vitro screening experiments, SIRT1 and SIRT5 agonists, namely, MC2606 and MC3215, at 1-20 μΜ were added to cardiomyoblasts (H9c2) and human endothelial cells (EA.hy-926) during 24 h hypoxia/2 h reoxygenation (H/R). SIRT1 and SIRT5 agonists mitigated H/R injury. Male C57BL/6J mice underwent 30 min ischemia (I) followed by 2 h or 24 h reperfusion (R). Mice received vehicle, the SIRT1 or SIRT5 agonists at 20 and 30 mg/kg at the 20th min of ischemia, and IS was quantified via triphenyl-tetrazolium chloride staining (n=5-7/group). MC3215-mediated SIRT5 activation reduced IS at 24 h R at 20mg/kg compared to controls (25.18±2.7% vs 38.80±4.7%). MC3215 treatment resulted in reduced protein malonylation in all experimental settings. Targeted mass-spectrometry-based metabolomics in the ischemic heart at the 10<sup>th</sup> min of R suggested increased fatty acid oxidation, as indicated by increased N<sup>3</sup>-Trimethyllysine and D-pantothenate. Concomitantly, molecular analysis indicated that the SIRT5 agonist activated AMPKα and Reperfusion Injury Salvage Kinase (RISK) pathway. Additionally, at 3 h reperfusion, MC3215 led to increased mitofusin 2 without altering apoptosis, paving towards improved mitochondrial dynamics. Co-administration of SIRT5 inhibitor, TW-37, abrogated MC3215-mediated cardioprotection.</p><p><strong>Conclusion: </strong>SIRT5 pharmacological agonism emerges as a novel cardioprotective target, leading to RISK pathway activation and mitochondria-related metabolic effects, converging at salvaging ischemic myocardium from I/R injury.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"5489-5505"},"PeriodicalIF":4.7000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214431/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cardioprotection Through Pharmacological Activation of Sirtuin 5 in a Murine Model of Acute Myocardial Infarction.\",\"authors\":\"Carola Castiello, Panagiotis Efentakis, Panagiota-Efstathia Nikolaou, Lydia Symeonidi, Christina Chania, Ioanna Barla, Ifigeneia Akrani, Nikolaos Kostomitsopoulos, Evangelos Gikas, Nikolaos S Thomaidis, Emmanuel Mikros, Petra Kleinbongard, Rossella Fioravanti, Clemens Zwergel, Sergio Valente, Antonello Mai, Ioanna Andreadou\",\"doi\":\"10.2147/DDDT.S509337\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Sirtuins (SIRTs) play a critical role in redox and metabolic regulation of the myocardium; however, the cardioprotective potential of SIRT5 in terms of infarct size (IS) reduction is still elusive. Herein, we employed the newly synthesized SIRT5-specific agonist, MC3215, developed by our group, to explore for the first time the pharmacological activation of SIRT5 as a target for cardioprotection.</p><p><strong>Methods and results: </strong>In in vitro screening experiments, SIRT1 and SIRT5 agonists, namely, MC2606 and MC3215, at 1-20 μΜ were added to cardiomyoblasts (H9c2) and human endothelial cells (EA.hy-926) during 24 h hypoxia/2 h reoxygenation (H/R). SIRT1 and SIRT5 agonists mitigated H/R injury. Male C57BL/6J mice underwent 30 min ischemia (I) followed by 2 h or 24 h reperfusion (R). Mice received vehicle, the SIRT1 or SIRT5 agonists at 20 and 30 mg/kg at the 20th min of ischemia, and IS was quantified via triphenyl-tetrazolium chloride staining (n=5-7/group). MC3215-mediated SIRT5 activation reduced IS at 24 h R at 20mg/kg compared to controls (25.18±2.7% vs 38.80±4.7%). MC3215 treatment resulted in reduced protein malonylation in all experimental settings. Targeted mass-spectrometry-based metabolomics in the ischemic heart at the 10<sup>th</sup> min of R suggested increased fatty acid oxidation, as indicated by increased N<sup>3</sup>-Trimethyllysine and D-pantothenate. Concomitantly, molecular analysis indicated that the SIRT5 agonist activated AMPKα and Reperfusion Injury Salvage Kinase (RISK) pathway. Additionally, at 3 h reperfusion, MC3215 led to increased mitofusin 2 without altering apoptosis, paving towards improved mitochondrial dynamics. Co-administration of SIRT5 inhibitor, TW-37, abrogated MC3215-mediated cardioprotection.</p><p><strong>Conclusion: </strong>SIRT5 pharmacological agonism emerges as a novel cardioprotective target, leading to RISK pathway activation and mitochondria-related metabolic effects, converging at salvaging ischemic myocardium from I/R injury.</p>\",\"PeriodicalId\":11290,\"journal\":{\"name\":\"Drug Design, Development and Therapy\",\"volume\":\"19 \",\"pages\":\"5489-5505\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214431/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Design, Development and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DDDT.S509337\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S509337","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
摘要
目的:Sirtuins (SIRTs)在心肌氧化还原和代谢调节中起关键作用;然而,SIRT5在减少梗死面积(IS)方面的心脏保护潜力仍然难以捉摸。本研究采用本课组新合成的SIRT5特异性激动剂MC3215,首次探索SIRT5作为心脏保护靶点的药理激活作用。方法与结果:在体外筛选实验中,将SIRT1和SIRT5激动剂MC2606和MC3215分别以1-20 μΜ的浓度加入到成心肌细胞(H9c2)和人内皮细胞(EA.hy-926)中,24h缺氧/ 2h复氧(h /R)。SIRT1和SIRT5激动剂减轻H/R损伤。雄性C57BL/6J小鼠缺血30 min (I),再灌注2 h或24 h (R)。小鼠在缺血第20分钟分别给药20、30 mg/kg的SIRT1或SIRT5激动剂,并通过氯化三苯四氮唑染色定量IS (n=5-7/组)。与对照组相比,mc3215介导的SIRT5激活在20mg/kg剂量下降低了IS(25.18±2.7% vs 38.80±4.7%)。在所有实验环境中,MC3215处理导致蛋白丙二醛化降低。在缺血心脏中,基于靶向质谱的代谢组学在R的第10分钟显示脂肪酸氧化增加,如n3 -三甲基赖氨酸和d -泛酸增加。同时,分子分析表明SIRT5激动剂激活AMPKα和再灌注损伤挽救激酶(RISK)通路。此外,在3小时再灌注时,MC3215导致mitofusin 2增加而不改变凋亡,为改善线粒体动力学铺平了道路。SIRT5抑制剂TW-37的联合给药,取消了mc3215介导的心脏保护。结论:SIRT5的药理激动作用作为一种新的心脏保护靶点出现,导致RISK通路激活和线粒体相关的代谢作用,集中于挽救I/R损伤的缺血心肌。
Cardioprotection Through Pharmacological Activation of Sirtuin 5 in a Murine Model of Acute Myocardial Infarction.
Purpose: Sirtuins (SIRTs) play a critical role in redox and metabolic regulation of the myocardium; however, the cardioprotective potential of SIRT5 in terms of infarct size (IS) reduction is still elusive. Herein, we employed the newly synthesized SIRT5-specific agonist, MC3215, developed by our group, to explore for the first time the pharmacological activation of SIRT5 as a target for cardioprotection.
Methods and results: In in vitro screening experiments, SIRT1 and SIRT5 agonists, namely, MC2606 and MC3215, at 1-20 μΜ were added to cardiomyoblasts (H9c2) and human endothelial cells (EA.hy-926) during 24 h hypoxia/2 h reoxygenation (H/R). SIRT1 and SIRT5 agonists mitigated H/R injury. Male C57BL/6J mice underwent 30 min ischemia (I) followed by 2 h or 24 h reperfusion (R). Mice received vehicle, the SIRT1 or SIRT5 agonists at 20 and 30 mg/kg at the 20th min of ischemia, and IS was quantified via triphenyl-tetrazolium chloride staining (n=5-7/group). MC3215-mediated SIRT5 activation reduced IS at 24 h R at 20mg/kg compared to controls (25.18±2.7% vs 38.80±4.7%). MC3215 treatment resulted in reduced protein malonylation in all experimental settings. Targeted mass-spectrometry-based metabolomics in the ischemic heart at the 10th min of R suggested increased fatty acid oxidation, as indicated by increased N3-Trimethyllysine and D-pantothenate. Concomitantly, molecular analysis indicated that the SIRT5 agonist activated AMPKα and Reperfusion Injury Salvage Kinase (RISK) pathway. Additionally, at 3 h reperfusion, MC3215 led to increased mitofusin 2 without altering apoptosis, paving towards improved mitochondrial dynamics. Co-administration of SIRT5 inhibitor, TW-37, abrogated MC3215-mediated cardioprotection.
Conclusion: SIRT5 pharmacological agonism emerges as a novel cardioprotective target, leading to RISK pathway activation and mitochondria-related metabolic effects, converging at salvaging ischemic myocardium from I/R injury.
期刊介绍:
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.